Emricasan is a liver-targeted antiapoptotic pan-caspase inhibitor.1,2 It has been investigated as a hepatoprotective agent in the treatment of liver ischemia3 and NASH/NAFLD liver injury4,5. Emricasan protected SNB-19 cells against cell death induced by Zika virus strains MR766, FSS13025, and PRVABC59.6 Emricasan improves the viability of hPSCs and their differentiated progeny when used in a small molecule cocktail (CEPT) containing chroman 1, polyamines and trans-ISRIB.7
* VAT and and shipping costs not included. Errors and price changes excepted